Agent Capital’s Post

Antibody-Drug Conjugates (ADCs) are reshaping the biotech landscape, with approved ADCs projected to exceed $30B in sales by 2030. This explosive growth has ignited a flurry of M&A activity as pharma giants race to get a piece of the action - such as Pfizer - Seagen, Gilead - Immunomedics. These deals have thinned out the pool of pure-play ADC biotechs in the public market. But innovation doesn't stop—companies like Mersana Therapeutics MacroGenics, Inc. ADC Therapeutics , Pyxis Oncology Bicycle Therapeutics , and Elevation Oncology are pushing the envelope with next-gen ADC platforms addressing linker stability, homogeneity, pharmacokinetics, and tumor selectivity. While M&As make headlines, there is momentum in partnerships and private funding. Emerging VC-backed stars are joining the ADC gold rush (e.g.,Tagworks Pharmaceuticals , TORL Biotherapeutics, LLC )

Happy Friday network! There has been quite a number of significant movements across the life science space over the last few weeks, wanted to highlight the few of you who may not be aware. Sanofi pays over $100 million upfront for neuroendocrine tumor RLT therapy: https://lnkd.in/ebfrv4cw Moderna aims to cut $1.1 billion in spending, cutting 5 programs with potentially more to come: https://lnkd.in/e9HKqZkR Bain Capital reveal $3 billion funding round to make big investment moves in biotech: https://lnkd.in/euG2Pwe6 Gilead Sciences pays Genesis Therapeutics $35 million for AI based drug discovery work: https://lnkd.in/eKruqapY #pharma #biotech #lifescience #biotechinvestment

Spinal Muscular Atrophy Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers: DelveInsight’s, “Spinal Muscular Atrophy Pipeline Insight 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal muscular atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by … Continue reading → #PharmaceuticalsBiotech

We are excited to announce Deciduous Therapeutics as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting. Deciduous Therapeutics is a San Francisco based, venture backed start-up focused on harnessing the immune system to treat diseases of aging. Specifically, the company is focused on restoring natural killer t-cell function to systemically ablate pathological senescent cells. The company had demonstrated that a single dose of its proprietary NKT agonist is able to selectively remove senescent cells, resulting in disease resolution in both fibrosis and metabolic disease models. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024 and register now at agingpharma.org https://lnkd.in/ggNnNTeh #ARDD2024 #DrugDiscovery #AgingResearch

CD-19 Market to Witness Significant Growth During the Study Period (2019-32), Assesses DelveInsight | Horizon Therapeutics, MorphoSys, Incyte, Novartis, Bristol-Myers Squibb, Legend Biotech, Janssen #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

A Stellar Year for Molecular Glues: Another Billion BioBucks Deal   The recent surge in investments for molecular glue degraders follows key PROTAC deals, including Arvinas’ $225 million partnership with Pfizer and AstraZeneca’s $1 billion collaboration with C4 Therapeutics, Inc. In 2024, major deals include:   October 2024 - Pfizer’s $1.5 billion agreement with TRIANA Biomedicines https://lnkd.in/g_MaZYG5 August 2024 - Eisai Co., Ltd.’s $1.5 billion partnership with Seed Therapeutics https://lnkd.in/gSNqDWk7 May 2024 - Takeda’s $1.2 billion collaboration with Degron Therapeutics https://lnkd.in/g-BTJbip February 2024 - Bristol Myers Squibb and VantAI's $674 million deal https://lnkd.in/g3uQhFp5 Novo Nordisk’s $1.46 billion agreement with Neomorph, Inc. https://lnkd.in/gJrd3T4w   Molecular glues and PROTACs (Proteolysis Targeting Chimeras) are groundbreaking approaches in targeted protein degradation. Molecular glues enhance interactions between target proteins and E3 ligases, while PROTACs link them for degradation, both addressing previously "undruggable" targets.   These developments underscore the growing potential of these innovative therapies.   #MolecularGlues #PROTACs #DrugDiscovery

⭐ WIll Actinium Be Big Pharma's Next Radiopharmaceuticals Acquisition? • Who should read this? Pharma BD&L executives, competitive intelligence professionals. • What is it? A dive into a potential acquisition target in a field of R&D that has seen a lot of M&A. • Why is it important? Billions of dollars are being spent by big pharma on acquiring companies in the radiopharmaceuticals space. This article explores the science and business profile of Actinium Pharmaceuticals, which attaches antibodies to radioisotopes to target blood cancers, and has been tipped as a takeover target. It plans to file for approval of its first therapy this year. Citeline Citeline Commercial #PharmBD #Pharmaintelligence

CD-19 Market to Witness Significant Growth During the Study Period (2019-32), Assesses DelveInsight | Horizon Therapeutics, MorphoSys, Incyte, Novartis, Bristol-Myers Squibb, Legend Biotech, Janssen #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Lisata Therapeutics, Inc. (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech companies over the past three years as they seek recognition in a market that has performed ‘a 180’ turn since the peak of Covid vaccines interest in the sector in 2021. Risk capital has been sidelined during this politically and economically volatile period, not just in life sciences, but across microcap markets internationally. More at #Proactive #ProactiveInvestors http://ow.ly/plvJ105uPj5

TransCode Therapeutics Reports Further Restructuring to